ASX Announcements

Memphasys is committed to providing shareholders with complete, up-to-the-minute information about the Company. Contact, stock, and corporate information can be found in this section of the website and on the Australian Securities Exchange.

21 September 2022 Appendix 2A- Application for Quotation of Securities

19 September 2022 Rights Issue Closure and Shortfall Notification

5 September 2022 Non-Renounceable Issue

5 September 2022 Appendix 3B 

31 August 2022 Full Year Statutory Accounts

31 August 2022 Preliminary Final Report

31 August 2022 Appendix 4G and Corporate Governance Statement

29 August 2022 Rights Issue Prospectus despatched

25 August 2022 Application for quotation of securities

18 August 2022 Rights Issue offer – Letter to ineligible shareholders 

18 August 2022 Non-Renounceable IssueWebsite Disclaimer

18 August 2022 Update – Proposed issue of securities – MEM

17 August 2022 Proposed issue of securities – MEM

17 August 2022 Reinstatement to Official Quotation

17 August 2022 $3.36 capital raising to accelerate FELIX commercialisation

11 August 2022 Court Orders Granted and update on Proposed Capital Raising

2 August 2022 Cleansing Statement 

29 July 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

29 July 2022 Suspension from Official Quotation

27 July 2022 Trading Halt 

28 June 2022 Monash IVF clinical study enrols first patient using FELIX

27 June 2022 Notification of cessation of securities – MEM

9 June 2022 Felix System commercialisation update

6 June 2022 Notification of cessation of securities – MEM

17 May 2022 Response to ASX Query

26 April 2022 Final Director’s Interest Notice SH

26 April 2022 Initial Director’s Interest Notice – RC

26 April 2022 Non-Exec Chair Appointment and Director Resignation

12 April 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

3 Mar 2022 Creating Novel fertility Solutions

25 Jan 2022 Quarterly Activities/Appendix 4C Cash Flow Report 

24 Jan 2022  Change of Directors Interest Notice

19 Jan 2022  Sale of existing Convertible Note to Peters Investments Pty Ltd

20 Dec 2021  Memphasys secures first Felix™ System commercial sale for clinical IVF use

9 Dec 2021  Memphasys & Monash IVF to commence clinical trial of Felix™ system to support regulatory applications and commercial sales

2 Dec 2021  Field data collection successfully completed using the prototype Samson stallion fertility diagnostic device

9 Oct 2021  Change of director’s interest notice

28 Sep 2021  Cleansing Notice – Section 708A(5)(e)

28 Sep 2021  Application for quotation of securities – MEM

20 Sep 2021  Acceleration of reproductive biotechnology portfolio

17 Sep 2021  Appendix 3G correction

17 Sep 2021  Notification regarding unquoted securities

10 Sep 2021  Change of Director’s Interest Notice – AC and AG

3 Sep 2021  Appendix 3G

1 Sep 2021  Notification regarding unquoted securities – MEM

1 Sep 2021  MEM reaches settlement agreement with Hydrix

31 Aug 2021  Commercial arrangement between Hydrix and Memphasys 

31 Aug 2021  FY21 Corporate Governance Statement and Appendix 4G

30 Aug 2021  FY21 Full Year Statutory Accounts

30 Aug 2021  Preliminary Final Report

24 Aug 2021  Results of General Meeting

20 Aug 2021  General Meeting to be held as a Virtual Meeting of members 

30 Jul 2021  Disclosure Document – Cleansing Notice

30 Jul 2021  Application for quotation of securities – MEM

30 Jul 2021  Notification regarding unquoted securities – MEM 

26 Jul 2021  Quarterly Activities/Appendix 4C Cash Flow Report

23 Jul 2021  Notice of General Meeting/Proxy Form

5 Jul 2021  Global andrology expert, Professor John Aitken, joins MEM

1 Jul 2021  Upgraded Felix Device verification passed

26 May 2021  Proposed issue of Securities – MEM

26 May 2021  Memphasys completes $3m capital raise

25 May 2021  Trading Halt

4 May 2021  Assisted reproductive biotechnology products update

4 May 2021  Prof. John Aitken receives distinguished andrology award

30 Apr 2021  Quarterly Cashflow Report

29 Apr 2021  Granted US patents strengthens IP portfolio

27 Apr 2021  Felix device – V&V progress and KOL study update

30 Mar 2021  FELIX device Verification and Validation process update

8 Mar 2021  Felix device validation testing delayed

26 Feb 2021  Half Yearly Report and Accounts

17 Feb 2021  Change of Director’s Interest Notice – Coutts

17 Feb 2021  Cancellation of Performance Options

2 Feb 2021  Disclosure Document – s708A cleansing notice

2 Feb 2021  Appendix 2A option conversion